Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
